Open label randomised trial of atomoxetine for attention deficit hyperactivity disorder (ADHD) in children with special educational needs.

Trial Profile

Open label randomised trial of atomoxetine for attention deficit hyperactivity disorder (ADHD) in children with special educational needs.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms HSEN - ATOM
  • Most Recent Events

    • 15 Jun 2017 Status changed from completed to discontinued as investigator Emily Simonoff (E.simonoff@iop.kcl.ac.uk) has confirmed that this trial has been stopped due to low recruitment.
    • 21 Jul 2012 Eli Lilly added as association as reported by European Clinical Trials Database.
    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2008-004827-44).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top